Xu Wu, Wu Dali, Li Cuilian, Yan Lingfei, Peng Bo, Luo Yang, Liu Dawei, Li Qing, Wang Tao
Department of Urology, The Fifth Affiliated Hospital, Southern Medical University, Guanzhou, China.
PeerJ. 2025 Aug 18;13:e19869. doi: 10.7717/peerj.19869. eCollection 2025.
Aldolase B (), functioning as a glycolytic enzyme, exhibits a controversial role in malignancies and demonstrates dual potential as both a tumor suppressor and cancer-promoting enzyme. Nevertheless, it is still uncertain if there is a relationship between levels, prognosis, and tumor-infiltrating lymphocytes in clear cell renal cell carcinoma (ccRCC).
This study aims to investigate the prognostic significance of in ccRCC and its potential association with clinicopathological features and tumor immune microenvironment. By integrating multi-database bioinformatics analysis and experimental validation, we seek to elucidate the role of in ccRCC progression and its potential as a predictive biomarker.
To ascertain the potential link between level, clinical parameters, and overall survival (OS) in individuals with ccRCC, we employed diverse databases, which include The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), the Human Protein Atlas (HPA) and The University of Alabama at Birmingham Cancer data analysis Portal (UALCAN). Furthermore, an in-depth analysis of the link between tumor-infiltrating immune cells (TIIC) and was carried out using the TIMER database. Immunohistochemistry (IHC) was applied to identify the level in a tissue microarray.
The expression of demonstrated a strong association with pathologic T stage, pathologic N stage, pathologic M stage, histologic grade, and gender. Decreased level was linked to unfavorable disease-specific survival (DSS), progress free interval (PFI), and OS outcomes ( < 0.001). Subsequently, a marked link was observed between level and a heightened presence of infiltrating Treg, Th17 cells, and neutrophils in ccRCC. IHC showed that the level in ccRCC samples was notably diminished relative to that in the adjacent normal tissues.
As a prospective predictive indicator for individuals with ccRCC, reduced level exhibited strong correlations with clinical characteristics, unfavorable outcomes, and immune infiltration in individuals with ccRCC.
醛缩酶B（）作为一种糖酵解酶，在恶性肿瘤中发挥着有争议的作用，具有作为肿瘤抑制因子和促癌酶的双重潜力。然而，在透明细胞肾细胞癌（ccRCC）中，醛缩酶B水平、预后与肿瘤浸润淋巴细胞之间是否存在关联仍不确定。
本研究旨在探讨醛缩酶B在ccRCC中的预后意义及其与临床病理特征和肿瘤免疫微环境的潜在关联。通过整合多数据库生物信息学分析和实验验证，我们试图阐明醛缩酶B在ccRCC进展中的作用及其作为预测生物标志物的潜力。
为了确定ccRCC患者醛缩酶B水平、临床参数与总生存期（OS）之间的潜在联系，我们使用了多个数据库，包括癌症基因组图谱（TCGA）、基因表达综合数据库（GEO）、人类蛋白质图谱（HPA）和阿拉巴马大学伯明翰分校癌症数据分析门户（UALCAN）。此外，使用TIMER数据库对肿瘤浸润免疫细胞（TIIC）与醛缩酶B之间的联系进行了深入分析。应用免疫组织化学（IHC）方法在组织芯片中鉴定醛缩酶B水平。
醛缩酶B的表达与病理T分期、病理N分期、病理M分期、组织学分级和性别密切相关。醛缩酶B水平降低与不良的疾病特异性生存期（DSS）、无进展生存期（PFI）和OS结果相关（< 0.001）。随后，观察到醛缩酶B水平与ccRCC中浸润性调节性T细胞、辅助性T细胞17和中性粒细胞数量增加之间存在显著联系。免疫组织化学显示，ccRCC样本中的醛缩酶B水平相对于相邻正常组织明显降低。
作为ccRCC患者的一种前瞻性预测指标，醛缩酶B水平降低与ccRCC患者的临床特征、不良预后和免疫浸润密切相关。
